Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s reshaping treatment for plaque psoriasis and other autoimmune diseases with a potentially improved safety profile.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs